CoChat

Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Open access
Jain, Nitin, Curran, Emily, Iyengar, Neil M., Diaz-Flores, Ernesto, Kunnavakkam, Rangesh, Popplewell, Leslie, Kirschbaum, Mark H., Karrison, Theodore, Erba, Harry P., Green, Margaret, Poire, Xavier, Koval, Greg, Shannon, Kevin, Reddy, Poluru L., Joseph, Loren, Atallah, Ehab L., Dy, Philip, Thomas, Sachdev P., Smith, Scott E., Doyle, L. Austin, Stadler, Walter M., Larson, Richard A., Stock, Wendy, Odenike, Olatoyosi · 2014 · Clinical Cancer Research
Cited by 115

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Purpose: The clinical relevance of targeting the RAS/RAF/MEK/ERK pathway, activated in 70% to 80% of patients with acute myelogenous leukemia (AML), is unknown. Experimental Design: Selumetinib is an oral small-molecule inhibitor of MAP–ERK kinase (MEK)-1/2. Forty-seven patients with relapsed/refractory AML or 60 years old or more with untreated AML were enrolled on a phase II study. Patients were stratified by FLT3 ITD mutation status. The primary endpoint was response rate (complete, partial, and minor). Leukemia cells were analyzed for extracellular signal—regulated kinase (ERK) and mTOR phosphorylation. Results: Common drug-related toxicities were grade 1–2 diarrhea, fatigue, nausea, vomiting, and skin rash. In the FLT3 wild-type cohort, six of 36 (17%) patients had a response [one partial response, three minor responses, two unconfirmed minor responses (uMR)]. No patient with FLT3 ITD responded. NRAS and KRAS mutations were detected in 7% and 2% of patients, respectively. The sole patient with KRAS mutation had uMR with hematologic improvement in platelets. Baseline p-ERK activation was observed in 85% of patients analyzed but did not correlate with a response. A single-nucleotide polymorphism (SNP) rs3733542 in exon 18 of the KIT gene was detected in significantly higher number of patients with response/stable disease compared with nonresponders (60% vs. 23%; P = 0.027). Conclusions: Selumetinib is associated with modest single-agent antileukemic activity in advanced AML. However, given its favorable toxicity profile, combination with drugs that target other signaling pathways in AML should be considered. The potential association of SNP rs3733542 in exon 18 of the KIT gene with antileukemic activity of selumetinib is intriguing, but will require validation in larger trials. Clin Cancer Res; 20(2); 490–8. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-13-1311

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 115

Metadata

Authors
Jain, N., Curran, E., Iyengar, N. M., Diaz-Flores, E., Kunnavakkam, R., Popplewell, L., Kirschbaum, M. H., Karrison, T., Erba, H. P., Green, M., Poire, X., Koval, G., Shannon, K., Reddy, P. L., Joseph, L., Atallah, E. L., Dy, P., Thomas, S. P., Smith, S. E., Doyle, L. A., Stadler, W. M., Larson, R. A., Stock, W., & Odenike, O.
Venue
Clinical Cancer Research
Published
2014-01-15
Volume
20
Issue
2
Pages
490-498
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2101590448
Cited by
115
References
5
FWCI
8.53
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-1311
The paper
Jain, N., Curran, E., Iyengar, N. M., Diaz-Flores, E., Kunnavakkam, R., Popplewell, L., Kirschbaum, M. H., Karrison, T., Erba, H. P., Green, M., Poire, X., Koval, G., Shannon, K., Reddy, P. L., Joseph, L., Atallah, E. L., Dy, P., Thomas, S. P., Smith, S. E., . . . Odenike, O. (2014). Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-1311

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.